← Back

Wire · opportunities

Celldex drug stumbles in eczema; Epigenetic editing startup cuts staff

Published

20 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at biopharmadive.com →

◆ Verified

Fusion42 · 20 November 2026 · Fusion42 review

Celldex Therapeutics discontinued development of its drug barzolvolimab for eczema after Phase 2 results failed to meet internal benchmarks, though it plans to pursue approval for chronic hives. Meanwhile, epigenetic editing startup NChroma Bio cut staff and halted testing of its hepatitis B program.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You face rising challenges in developing immunological drugs as failed eczema trials trim Celldex’s prospects and reduce investor enthusiasm. Now is the time to reevaluate your drug candidate positioning and risk exposure in immune disorders.

◆ Coverage

1 source · 20 Nov 2026

◆ Related on Wire

◆ Topics

Biotechclinical-trialdrug-developmentbiotecheczemahepatitis-b